on, mar 21, 2018 07:37 CET
Redeye initiates analyst coverage of Xspray Pharma, a Swedish biopharma with a unique business model. Three product candidates are lined up to reach the market between 2020-2023, and it is our belief that Xspray can utilize their RightSize technology platform to become a niche generic player that can out-maneuver other market players.
Fair value in our Base Case indicates about 80% upside from current share price. Read more and download the research report by Mathias Spinnars: https://goo.gl/TSPBjk
Start following Xspray Pharma at Redeye to instantly receive our latest analyst updates and comments.
This is a press release from Redeye – Research Powered Investment Banking. https://www.redeye.se/about/